Rize Oncology Inc.
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.46% | 16.15% | 1.40% | -3.85% | -43.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.46% | 0.35% | -21.17% | -5.13% | -42.64% |
| Operating Income | -49.46% | -0.35% | 21.17% | 5.13% | 42.64% |
| Income Before Tax | -62.03% | -7.02% | 19.96% | 7.03% | 46.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.03% | -7.02% | 19.96% | 7.03% | 46.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.03% | -7.02% | 19.96% | 7.03% | 46.97% |
| EBIT | -49.46% | -0.35% | 21.17% | 5.13% | 42.64% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -9.21% | 7.84% | 10.13% | 16.36% | 47.95% |
| Normalized Basic EPS | -10.64% | 7.37% | 10.20% | 16.54% | 48.07% |
| EPS Diluted | -9.21% | 7.84% | 10.13% | 16.36% | 47.95% |
| Normalized Diluted EPS | -10.64% | 7.37% | 10.20% | 16.54% | 48.07% |
| Average Basic Shares Outstanding | 36.57% | 7.87% | -16.24% | -10.36% | -4.08% |
| Average Diluted Shares Outstanding | 36.57% | 7.87% | -16.24% | -10.36% | -4.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |